Medical Technology Assessment Group / MEDLINE / Genzyme Australasia Pty Ltd / M-TAG Pty Ltd / /
Country
Australia / /
Event
Product Recall / Product Issues / /
Facility
Incidence The Australian Institute of Health / /
Holiday
Commonwealth Day of Australia / /
IndustryTerm
search strategies / search strategy / health technology assessment / treatment of recurrent or residual disease / hich medical services / radioiodine imaging / /
MedicalCondition
well-differentiated thyroid cancer / residual disease / differentiated thyroid cancer / headache / non-melanoma skin cancers / nausea / severe hypothyroidism / metastatic disease / well-differentiated thyr oid cancer / fatigue / hypoparathyroidism / follicular thyroid cancer / occasional significant illness / constipation / papillary and follicular cancer / cancers / cancer / disease / recurrent cancer / hypothyroidism / tumour / pain / well-differentiated thyroid cancer ranging / depression / metastases / thyroid cancer / laryngeal nerve injury / /
MedicalTreatment
thyroid hormone therapy / /
Organization
Supporting committee / rhTSH administration / Commonwealth Government / Medicare / Australian Institute of Health and Welfare / Department of Health / Medical Services Advisory Committee / /
Person
Paul Mernagh / Lachlan Standfield / Adèle Weston / /
Position
Commonwealth Minister / Manager / Legislative Services / General / Commonw ealth Minister / Secretary / Governor / Executive / well-differentiated thyr oid cancer Executive / /
Product
rhTSH-stimulated/THT / thyroglobulin / method / effectiveness / arm of the modelled economic evaluation / arm of the secondary modelled economic evaluation / arm / Thyrogen / serum Tg effectiveness / THT / /
Recombinant human thyroidstimulating hormone (rhTSH) Diagnostic agent for use in well-differentiated thyroid cancer August 2002